Horizons In Cancer Research
Download Horizons In Cancer Research full books in PDF, epub, and Kindle. Read online free Horizons In Cancer Research ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
| Author | : Surajit Pathak |
| Publisher | : Springer Nature |
| Total Pages | : 369 |
| Release | : 2020-10-17 |
| Genre | : Medical |
| ISBN | : 9811551200 |
This book discusses the recent developments in the therapeutic implications of cancer stem cells for the effective diagnosis, prognosis, and treatment of cancer. It summarizes the various stem cells of common cancers including colon, pancreas, lungs, prostate, melanoma, and glioblastoma, and reviews the potential role of cancer stem cells in tissue aggressiveness, examining the functional contribution of cancer stem cells in the establishment and recurrence of cancerous tumors. Further, it explores the potential of cancer stem cells as novel therapeutic targets for the treatment and prevention of tumor progression. The book also discusses the various approaches for detecting, isolating, and characterizing different cancer stem cells and signaling pathways that control their replication, survival, and differentiation. Lastly, it explores the key features and mechanisms of drug resistance, chemo-resistance, and radio-resistance in cancer stem cells to improve therapeutic rationale.
| Author | : Hiroto S. Watanabe |
| Publisher | : |
| Total Pages | : 0 |
| Release | : 2021-06-11 |
| Genre | : Medical |
| ISBN | : 9781536195637 |
This edited volume presents six chapters detailing recent progress in the field of cancer research. Chapter One discusses the current information available regarding chemotherapy-induced peripheral neuropathy, including definition, prevalence, pathophysiology at nerve fibers, risk factors, physiology of specific antineoplastic agents on the peripheral nervous system, signs and symptoms, diagnostic criteria, and treatment methods. Chapter Two aims to substantiate the value of tumor-associated circulating and tissue miRNAs for assessing both the aggressiveness of the malignant process course and the sensitivity to neoadjuvant polychemotherapy (NPCT) in breast cancer patients of various molecular subtypes. Chapter Three summarizes the current role of nuclear factor kappa B (NF-κB) in cell aging, its dual functions in the balance of proliferation and apoptosis pathways and the current knowledge of not only the physiological but also the pathophysiological missions of NF-κB and its potential role as a target of therapeutic intervention against breast cancer. Chapter Four deals with 5-aminolevulinic acid radiodynamic therapy for treatment of high-grade gliomas. Chapter Five presents a literature review to identify the possible role of sex hormone receptors in gender variation and sexual dimorphism in the genesis and progression of urothelial bladder cancer (UBC). Lastly, Chapter Six discusses the risk factors, diagnostic modalities, and outcomes of cholangiocarcinoma (CCA), the second most common primary hepatobiliary malignancy.
| Author | : Konstantinos N. Chatzigeorgiou |
| Publisher | : Nova Science Publishers |
| Total Pages | : 234 |
| Release | : 2005 |
| Genre | : Metastasis |
| ISBN | : |
Ovarian cancer is the most common cause of death among all gynecological neoplasms. Ovarian epithelial cancer represents approximately 90% of all ovarian malignant tumours. The most usual pattern of spread and probably the earliest kind of metastasis of ovarian cancer is intraperitoneal spread, caused by apoptosis of viable cancer cells, even in cases where the ovarian surface has no visible rupture. Approximately 70% to 75% of all ovarian cancers are being diagnosed with peritoneal carcinomatosis and ascites in advanced stages III and IV. Peritoneal carcinomatosis from ovarian cancer may occur either concomitantly with the primary tumour or as a recurrence pattern of spread. Standard treatment consists of surgical debulking and postoperative systemic chemotherapy. Response rates to first-line chemotherapy with platinum/taxane combinations are high, about 70-80%, but the vast majority of patients will relapse. Peritoneal seeding is a major cause of surgical treatment failure among those patients, even after optimal debulking. However, progressing ovarian cancer tends to remain within the peritoneal cavity or, better-expressed, ovarian cancer is a cancer of the peritoneum. The administration of cytotoxic agents directly into the peritoneal cavity as treatment for malignancy was initially evaluated more than 40 years ago. Over the past two decades regional therapy of ovarian cancer has evolved from just an interesting pharmacokinetic concept into a viable management option for women with advanced disease. Several authors, and among them some of the world's leading experts on this field present the current knowledge and their experience on peritoneal carcinomatosis from ovarian cancer.
| Author | : |
| Publisher | : |
| Total Pages | : |
| Release | : 2004 |
| Genre | : |
| ISBN | : |
| Author | : Hiroto S. Watanabe |
| Publisher | : Nova Science Publishers |
| Total Pages | : 0 |
| Release | : 2011 |
| Genre | : Cancer |
| ISBN | : 9781612093772 |
Annotation. 'Horizons in Cancer Research' presents original research results on the leading edge of cancer research. Each article has been carefully selected in an attempt to present substantial research results across a broad spectrum.
| Author | : Jack H. Mydlo |
| Publisher | : Elsevier |
| Total Pages | : 601 |
| Release | : 2003-07-11 |
| Genre | : Science |
| ISBN | : 0080497896 |
An important translational book bridging the gap between science and clinical medicine, Prostate Cancer reviews the biological processes that can be implicated in the disease, reviews current treatments, highlighting the pitfalls where relevant and examines the scientific developments that might result in novel treatments in the future.Key Features* Provides a translational resource for scientists and clinicians working on prostate cancer* Reviews current surgical interventions and highlights their related pitfalls* Presents the latest laparoscopic techniques with figures and illustrations of step-by-step procedures* Offers insight into the potential for novel approaches to treatment in the future* Includes personal perspectives from patients
| Author | : Solomon P. Wasser |
| Publisher | : Elsevier |
| Total Pages | : 382 |
| Release | : 2021-08-04 |
| Genre | : Science |
| ISBN | : 0323907520 |
New Horizons in Evolution is a compendium of the latest research, analyses, and theories of evolutionary biology. Chapters are collected from the international symposium held by the Board of Governors of the University of Haifa to honor Dr. Eviatar Nevo, founder and director of the Institute of Evolution. This book includes material written by top global scientists. Such detailed summaries and recent advances include topics like genomics, epigenetics, evolutionary theory, and the evolution of cancer. This book analyzes evolutionary biology of animals, such as lizards and subterranean mammals. It also discusses agricultural evolution, specifically the vital wheat crop in various climates and locations. Each chapter contributes the most up-to-date knowledge of evolution's role in speciation, adaptation, and regulation. New Horizons in Evolution is a valuable resource for researchers involved in evolution, evolutionary biology, and evolutionary theory. Advanced undergraduate and graduate students in evolutionary biology courses will also find this useful due to the high expertise level and latest knowledge available through this resource. Examines the evolution of species in extreme conditions Discusses the role of evolution in medicine and cancer research Features the latest data and advances in evolution theory
| Author | : Neil P. Ruzic |
| Publisher | : University of Illinois Press |
| Total Pages | : 458 |
| Release | : 2003 |
| Genre | : Biological response modifiers |
| ISBN | : 9780252028670 |
A scathing critique of the chemotherapy culture as well as unscientific "alternative" therapies, the book endorses state-of-the-art molecularly based technologies, making it an illuminating and necessary read for anyone interested in cancer research, especially patients and their families and physicians.
| Author | : Shiu Y. Tsao |
| Publisher | : Nova Science Publishers |
| Total Pages | : 0 |
| Release | : 2021 |
| Genre | : Medical |
| ISBN | : 9781536199000 |
Recognising rare diseases' impracticability of having extensive clinical trials necessary for regulatory approval, the US Orphan Drug Act appropriately facilitates the commercialization of "orphan drugs". However, even common cancers also have rather specific but uncommon clinical situations for which extensive clinical trials are hardly practicable. Moreover, although such very costly and extensive trials often depend on industry support, uncommon situations are unattractive. Eventually, many specific treatments for designated clinical oncology situations often lack regulatory approvals merely because of suboptimal trial data. Now, this EBM (evidence-based medicine) book by expert authors with first-hand clinical experience is about off-label but acceptable treatment options. The attempt is to patch up the low response rates and considerable adverse events of novel immunotherapy. Currently, without any such off-label treatments, some cancer patients may well be left out in the cold. Although off-label treatments lack regulatory approval, they are backed by EBM and have good safety profiles. It's inappropriate to announce "nothing else can be done" merely because all approved options have already been exhausted. In expert hands, despite the "on compassionate grounds" proviso, the safety profiles of such off-label prescriptions may even compare favourably with orthodox chemotherapy given at top doses.
| Author | : Marc Damelin |
| Publisher | : Springer |
| Total Pages | : 358 |
| Release | : 2018-05-29 |
| Genre | : Medical |
| ISBN | : 3319781545 |
Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field’s history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties. However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing. The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies. These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients.
